China · Delayed Price · Currency is CNY Hangzhou Tigermed Consulting Company Description
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally.
It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services.
It also provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services.
In addition, the company offers patient recruitment, investment management, medical registration, pharmaceuticals and regulations consulting, drug safety, bioequivalence, and third-party training services, as well as chemistry, management, and controls services.
Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People’s Republic of China.
| Country | China |
| Founded | 2004 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 10,185 |
| CEO | Xiaochun Cao |
Contact Details
Address: Shengda Science Park, Building A Hangzhou, Zhejiang Province 310051 China | |
| Phone | 86 571 2888 7227 |
| Website | tigermedgrp.com |
Stock Details
| Ticker Symbol | 300347 |
| Exchange | Shenzhen Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100001KV8 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Dr. Xiaoping Ye D.Phil, EMBA, M.D., Ph.D. | Co-Founder and Chairman |
| Dr. Xiaochun Cao M.D. | Co-Founder, GM and Executive Director |
| Hao Wu | President and Executive Director |
| Chengcheng Yang | Chief Financial Officer |
| Zengyu Wen | Executive Vice President, Chief Operating Officer and Executive Director |
| Xiao Ri Li | Secretary |
| Dr. Tianrong Ji M.D., Ph.D. | Chief Investment Officer |
| Guoyun Yu | Head of Accounting Department |
| Jiansong Yang Ph.D. | Senior Vice President and Chief Scientific Officer |
| Mo Shuang | Chief Compliance Officer |